New hire elevates strategic labeling solutions to support faster approval and smarter commercialization.
RALEIGH, July 8, 2025 – ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners, today announced that Marshall Florence, PharmD, has joined as its new Vice President, Labeling. In this role, he will lead compliance and regulatory advisory services for pharmaceutical, biotechnology, medical device, and diagnostic companies.
Prior to arriving at ProPharma, he was a Supervisory Pharmacist with the U.S. Food and Drug Administration’s Division of Labeling Review, where he served as an FDA representative on the Tall Man Lettering Study and a member of the Safety Labeling Group. In this role, he oversaw primary and secondary review of drug product labeling and established and led the Best Pharmaceuticals for Children Act (BPCA) Working Group. Florence brings 15 years of progressive leadership experience in Regulatory Promotional Review & Labeling Services, is an expert in strategic labeling development, and provides deep insight into how to craft labels that support business goals while staying compliant.
“We’re thrilled to welcome Marshall as a senior leader on ProPharma’s Regulatory Sciences team,” said Matthew Weinberg, ProPharma’s President, Regulatory Sciences. “His leadership experience at FDA and deep expertise in strategic label development significantly elevate our capabilities in advertising, promotional review, and drug development. His unique insight into the regulatory landscape—particularly for new molecular entities, generics, and products with complex exclusivity considerations—will bring immense value to our clients. This addition strengthens our industry-leading ability to guide companies through the full development lifecycle, including labeling strategy with precision, innovation, and compliance."
ProPharma is the world’s leading regulatory science consultancy, and Florence's addition will enable ProPharma clients to think about labeling from not only a regulatory angle but as part of a broader development strategy, especially regarding patent exclusivity, new molecular entities (NMEs), and generics. Florence is scheduled to host a webinar on July 22, 2025, where he will discuss how to craft high-quality ANDA submissions and avoid common pitfalls that lead to CRLs. Please visit our Inside FDA Review: Crafting a Quality ANDA Labeling Submission Webinar registration page for more information and registration details.
About ProPharma
For more than 25 years, ProPharma has improved the health and wellness of patients by providing advice and expertise that empowers biotech, med device, and pharmaceutical organizations of all sizes to confidently advance scientific breakthroughs and introduce new therapies. With deep domain expertise in regulatory sciences, clinical research solutions, quality and compliance, pharmacovigilance, medical information, and R&D technology, ProPharma offers an end-to-end suite of fully customizable consulting solutions that de-risk and accelerate our partners’ most high-profile drug and device programs. For more information about ProPharma, please visit propharmagroup.com.
About Odyssey Investment Partners
Odyssey Investment Partners is a leading private equity investment firm with more than a 25-year history of partnering with skilled managers to transform middle-market companies into more efficient and diversified businesses with strong growth profiles. Odyssey makes majority-controlled investments in industries with a long-term positive outlook and favorable secular trends. For further information about Odyssey, please visit odysseyinvestment.com.
###
Media Contact:
Shannon Severino
shannon@severinocommunications.com
